Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Duffaud

Showing results (31-40 of 132) with videos related to

Pageof 14
Sort By:
Oncology Letters|March 15, 2019
Rechallenge of carboplatin-gemcitabine based chemotherapy for rapidly progressing metastatic collecting duct carcinoma of the kidney leading to a delayed and durable complete response: A case reportDomitille Dano, Clémence Delteil, Romain Boissier, et al.
Trials|August 13, 2014
Efficacy of lidocaine in patients receiving palliative care with opioid-refractory cancer pain with a neuropathic component: study protocol for a randomized controlled studySébastien Salas, Pascal Auquier, Florence Duffaud, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Bulletin Du Cancer|August 22, 2018
[Proton therapy in soft tissue and bone sarcomas]Juliette Thariat, Thomas Tessonnier, Sylvie Bonvalot, et al.
American Journal of Clinical Pathology|March 21, 2003
CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patientsJean-Philippe Dales, Stephane Garcia, Pascal Bonnier, et al.
Clinical Genitourinary Cancer|December 25, 2024
A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs InitiationPierre Grassi, Werner Hilgers, Romain Boissier, et al.
International Journal of Oncology|January 16, 2003
Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patientsJean-Philippe Dales, Stéphane Garcia, Pascal Bonnier, et al.
Oncotarget|May 3, 2018
Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCRNicolas Macagno, Frédéric Fina, Nicolas Penel, et al.
Health and Quality of Life Outcomes|April 29, 2017
Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal studySebastien Salas, Sophie Mercier, Benjamin Moheng, et al.
Annales De Pathologie|November 5, 2003
[Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma]Jean-Philippe Dales, Stéphane Garcia, Pascal Bonnier, et al.
Pageof 14

Showing results (31-40 of 132) with videos related to

Sort By:
Pageof 14
Oncology Letters|March 15, 2019
Rechallenge of carboplatin-gemcitabine based chemotherapy for rapidly progressing metastatic collecting duct carcinoma of the kidney leading to a delayed and durable complete response: A case reportDomitille Dano, Clémence Delteil, Romain Boissier, et al.
Trials|August 13, 2014
Efficacy of lidocaine in patients receiving palliative care with opioid-refractory cancer pain with a neuropathic component: study protocol for a randomized controlled studySébastien Salas, Pascal Auquier, Florence Duffaud, et al.
Clinical Cancer Drugs|April 24, 2018
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTSManon Launay, Joseph Ciccolini, Claire Fournel, et al.
Bulletin Du Cancer|August 22, 2018
[Proton therapy in soft tissue and bone sarcomas]Juliette Thariat, Thomas Tessonnier, Sylvie Bonvalot, et al.
American Journal of Clinical Pathology|March 21, 2003
CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patientsJean-Philippe Dales, Stephane Garcia, Pascal Bonnier, et al.
Clinical Genitourinary Cancer|December 25, 2024
A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs InitiationPierre Grassi, Werner Hilgers, Romain Boissier, et al.
International Journal of Oncology|January 16, 2003
Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patientsJean-Philippe Dales, Stéphane Garcia, Pascal Bonnier, et al.
Oncotarget|May 3, 2018
Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCRNicolas Macagno, Frédéric Fina, Nicolas Penel, et al.
Health and Quality of Life Outcomes|April 29, 2017
Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal studySebastien Salas, Sophie Mercier, Benjamin Moheng, et al.
Annales De Pathologie|November 5, 2003
[Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma]Jean-Philippe Dales, Stéphane Garcia, Pascal Bonnier, et al.
Pageof 14